Recent XLO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 08:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 08:30:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:06:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:15:17 PM
- Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors • GlobeNewswire Inc. • 06/13/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 12:09:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 11:45:14 AM
- Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/07/2024 04:15:40 AM
- Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/01/2024 08:05:00 PM
- Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing • GlobeNewswire Inc. • 03/28/2024 11:05:00 AM
- Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program • Business Wire • 03/28/2024 11:00:00 AM
- Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/28/2024 09:01:00 PM
- Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference • GlobeNewswire Inc. • 01/31/2024 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:30:28 PM
- Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies • GlobeNewswire Inc. • 01/08/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:38:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:15:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:15:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 09:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 12:45:19 PM
- Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data • GlobeNewswire Inc. • 12/07/2023 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:17:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:13:39 PM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM
Kona Gold Beverage Significantly Reduces Debt from Multiple Holders • KGKG • Jul 31, 2024 9:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • ELMGF • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM